Neurofibromatosis Type 2
16
1
3
9
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
18.8%
3 terminated out of 16 trials
75.0%
-11.5% vs benchmark
0%
0 trials in Phase 3/4
56%
5 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (16)
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
Doxycycline in Cutaneous Schwannoma (NF2)
Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma
Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas
Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma
Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas
Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas
Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas
Effect of Implant Position on Magnetic Resonance Image Distortion
Compassionate Use Arm - ABI541 ABI for 10 NF2 Patients
Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2)
WES of NF2-associated in Comparison to Sporadic Vestibular Schwannomas - Correlation With Clinical Data
Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors